Home
University & Research Institutions

Sector: University & Research Institutions

Historic CRISPR drug approval heralds new era in Cas9 IP wars

Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.

CRISPR-Cas9 drugmakers like Vertex should come to the table early, says ToolGen’s IP chief

Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals

Patent transactions in Q2 2023

The surge is due to 9,702 US patent assets involved in the BlackBerry sale to Key Patent Innovations, which runs Malikie Innovations, according to the AST Patent Deals Report for Q2 2023

Latest content

Stealthy biotech buys up patent portfolios in string of recent deals

Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months

04 May 2022

Columbia University scores $185 million jury verdict on back of anti virus patents

NortonLifeLock has pledged to appeal the jury verdict, which could balloon to $550 million with enhanced damages for wilful infringement

03 May 2022

CRISPR FTO complexities not going anywhere in wake of Broad Institute victory, says IP chief on the CVC side

Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech

04 April 2022

Five key takeaways from IPBC Europe

Returning from two action-packed days in London, IAM Deputy Editor Adam Houldsworth reflects on the surprising state of corporate UPC strategies, the rise of AI, FRAND fireworks and more

02 April 2022

MPEG LA chief calls on rights owners to make CRISPR patent pool a reality

Larry Horn speaks exclusively to IAM about the future of biotech joint licensing programmes

25 March 2022

JPO presses case for grace period harmony as trade deals bring issue to the fore

The grace period gap between major jurisdictions has recently been thrust into the spotlight. The JPO is one stakeholder pushing for major players to seize momentum and work towards harmonisation

23 March 2022

Sanofi scores $300 million in unusual royalty deal

Deal announced by French pharma giant this week is highly distinctive, but also reflects several recent trends in the booming drug revenue market

17 March 2022

Breakthrough in TRIPS covid waiver negotiations – here’s what you need to know

There are reports of a compromise deal agreeed by the US, EU, India and South Africa, but no official confirmation

16 March 2022

Vaccine hub leader welcomes new Moderna patent pledge, but calls for collaboration

Petro Terblanche speaks to IAM about the mRNA innovator’s expanded IP commitment

14 March 2022

Medical device maker is latest to tap secondary market for wireless patents

A recent deal shows that a wider selection of corporates are exploring acquisition opportunities and working with custom R&D labs

08 March 2022

Unlock unlimited access to all IAM content